Smith Nicholas Conrad, the President and CFO of Alto Neuroscience, Inc., recently acquired 55,000 shares of the company's common stock. The transaction occurred on October 2, 2026, at a price of $2.32 per share. This acquisition is significant as it reflects the confidence of a high-ranking executive in the company’s future prospects.
Alto Neuroscience, Inc. operates within the pharmaceutical preparations sector. The company is incorporated in Delaware and has its business address in Mountain View, California. Alto Neuroscience focuses on developing innovative therapies to address mental health conditions.
According to the recent SEC filing, the transaction was reported under Form 4, which indicates that it was an acquisition of shares. Following this transaction, Conrad now holds a total of 79,060 shares in Alto Neuroscience. The filing states, "Transaction Date: 2026-10-02, Transaction Amounts: 55,000 shares acquired." This indicates a direct ownership of the shares acquired.
This acquisition may influence various stakeholders, including investors, employees, and market analysts, as it showcases the commitment of the company's leadership to its growth and stability. The pharmaceutical industry is continually evolving, and such insider transactions can provide insights into the confidence levels of executives regarding their company's trajectory.
Details were not available in the SEC filing regarding any upcoming events or further actions following this acquisition.